Lawsuits alleging GLP-1 drugs led to blindness to be centralized

Post Content
Noom Pivots to Longevity: New Program Combines Microdose GLP-1s with At-Home Biomarker Testing

What You Should Know: – Noom has launched Proactive Health Microdose GLP-1Rx, a first-of-its-kind preventive health program designed to intervene before chronic disease takes root. – Available to individuals with a BMI of 21 or higher, the offering combines personalized microdoses of GLP-1 medication with comprehensive at-home biomarker testing and Noom’s digital behavior modification platform. […]
PHTI Report 2025: 5 Strategies for Employers to Manage GLP-1 Costs and Coverage

What You Should Know: – The Peterson Health Technology Institute (PHTI) has released a critical purchasing guide for employers struggling to manage the skyrocketing costs of GLP-1 obesity medications. – The report recommends a shift away from broad, unchecked coverage toward a managed approach focused on three phases: Initiation (strict eligibility), Maintenance (adherence support), and […]
GLP-1 medications may Lower Epilepsy Risk in individuals with type 2 diabetes, according to a recent study. Drugs that mimic the action of the hormone glucagon-like peptide-1 (GLP-1) include semaglutide.

submitted by /u/ranjitsingh7 [link] [comments]
Inclusive Sizing Leaders FullBeauty and Destination XL Combine in ‘Merger of Equals’

Destination XL Group (DXL) and FullBeauty Brands, both giants in the big-and-tall/inclusive-sizing category, will combine in a “merger of equals” with combined net sales of $1.2 billion for the year that ended in October 2025. The deal, which has been approved by both companies’ boards, is expected to generate $25 million in annual run-rate cost […]
The GLP-1 effect: How 2026 will look for food and beverage

From shifting grocery habits to new product opportunities, Circana’s insights reveal how brands and retailers can adapt to the rise of GLP-1 users.
Inspire Medical Systems (INSP) Fell Following Reduced Full-Year Guidance

Wasatch Global Investors, an asset management company, released its third-quarter 2025 “Wasatch Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. US small-cap equities rallied strongly in the third quarter. The Fed Reserve’s interest rate cut supported the rally. However, the fund-Investor Class struggled to keep up with the […]
‘The role of Ozempic isn’t just about reduced consumption, it’s about a shift in values’

Weight loss medications are quietly reshaping how and why people drink, pushing alcohol towards a more selective and health-aware future. James Bayley asks whether health can be pursued without losing autonomy. The rise of GLP-1 medications such as Ozempic is no longer a background murmur for the drinks trade. It is becoming a decisive force […]
Perfect Day says Gujarat facility on track for 2026 start, 2027 ramp-up for recombinant whey protein

Perfect Day—a pioneer in the “animal-free dairy” space making whey proteins via precision fermentation—says it expects initial operations to begin at its new production facility in Gujarat, India, in the second half of 2026. This will be followed by a “controlled ramp-up” into 2027. The firm, which has raised more than $825 million since it […]
Would I be mad to buy more Diageo shares near £16?

Diageo‘s (LSE: DGE) been one of the worst-performing shares in my ISA this year. Year to date, the share price is down about 35%. Would I be mad to buy more while theyâre near £16? Letâs discuss. Five reasons I might buy Iâve been closely monitoring Diageo shares while theyâve been falling and getting increasingly […]